Prevent Cancer- Greenville (CCPW)

Prevent Cancer-Greenville: A Center for Cancer Prevention and Wellness Research Project

Prevent Cancer-Greenville was created to provide individuals with the opportunity to have their risk of developing cancer studied. Some individuals may be at a higher risk due to their personal lifestyle, family history and/or exposures. If subjects are found to be at high risk for developing a disease, they will be sent to a healthcare provider for further care.

Study Overview

• Status: Recruiting
• Conditions: Cancer; High-Risk Cancer

Detailed Description

Participants' personal history, lifestyle behaviors and blood, urine, and cheek swab specimens will be used to detect changes or trends that might put them at risk for developing cancer. Some individuals may be at an above average risk of cancer due to lifestyle, family background, personal genetic makeup, or environmental exposures. This will be determined by a process called risk stratification. Risk stratification involves looking at all health-related aspects of a person, determining their individualized risk through screening, and educating them on measures to reduce potential for disease. Participants will complete a yearly health assessment which includes measurements for nutrition, activity, individual risk factors and body composition, including weight height and a special scale which measures fluid and fat.

• Study Type: Observational
• Enrollment (Estimated): 1000

Contacts and Locations

• Study Contact: Name: Patricia Wilson, MSN Ed. OCN ONNCG; Phone Number: 864-455-4897; Email: CCPW@prismahealth.org

Study Locations

• United States
  • South Carolina
    • Greenville, South Carolina, United States, 29605
      • Recruiting
      • Prisma Health-Upstate
      • Principal Investigator: Joe Stephenson, MD
      • Contact: Patricia Wilson, MSN Ed. OCN ONNCG; Phone Number: 864-455-4897; Email: CCPW@prismahealth.org

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: Yes

• Sampling Method: Non-Probability Sample

Study Population

Individuals 18 years or older

Description

Inclusion Criteria:

• 18 years or older

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Assess changes in nutrition by nutrition questionnaire	Nutrition will be assessed yearly by a questionnaire based on nutrition recommendations from the American Institute for Cancer Research and the U.S. Department of Health and Human Services.	Yearly follow up for 10 years
Assess changes in physical activity by physical activity questionnaire	Physical activity will be assessed yearly a questionnaire based on physical activity recommendations from the U.S. Department of Health and Human Services.	Yearly follow up for 10 years
Assess changes in smoking habits	Participants will be educated on healthy lifestyle habits and smoking habits will be assessed yearly.	Yearly follow up for 10 years
Assess changes in alcohol use	Participants will be educated on healthy lifestyle habits and alcohol use will be assessed yearly.	Yearly follow up for 10 years
Assess hereditary risk through family history review	Each participant's family history will be reviewed to make recommendations for screening or genetic testing based on National Comprehensive Cancer Network guidelines.	Yearly follow up for 10 years
Assess lifetime breast cancer risk through the Tyrer-Cuzick version 8 breast risk evaluation tool	Participants' breast cancer risk will be assessed using the Tyrer-Cuzick breast cancer risk model. Participants will be referred to appropriate clinics if lifetime risk is greater than 20 percent.	Yearly follow up for 10 years
Assess 5- year breast cancer risk through the GAIL breast risk evaluation tool	Participants' breast cancer risk will be assessed using the National Cancer Institute's GAIL model. Participants will be referred to appropriate clinics if GAIL 5 year risk is greater than 1.7 percent.	Yearly follow up for 10 years
Early detection of malignancies through screening	Participants will be educated on screening recommendations by the American Cancer Society. Malignancies will be recorded yearly if found by recommended screenings.	Yearly follow up for 10 years
Assess changes in fat mass by SOZO measurements	Body composition will be assessed yearly by measurements taken from the SOZO device which uses bioimpedance spectroscopy to measure fat mass.	Yearly follow up for 10 years
Assess changes in muscle mass by SOZO measurements	Body composition will be assessed yearly by measurements taken from the SOZO device which uses bioimpedance spectroscopy to measure muscle mass.	Yearly follow up for 10 years

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Assess changes in quality of life by the 5-level EuroQol-5D version (EQ-5D-5L) questionnaire	Quality of life will be assessed yearly by the EQ-5D-5L questionnaire. Participants' will self-report their health on a scale numbered 0-100. 100 means the best health you can imagine and 0 means the worst health you can imagine.	Yearly follow up for 10 years

Collaborators and Investigators

• Sponsor: Prisma Health-Upstate
• Investigators: Principal Investigator: Joe Stephenson, MD, Prisma Health-Upstate

Publications and helpful links

Helpful Links

• Education resources
• Screening guidelines

Study record dates

Study Major Dates

• Study Start (Actual): November 8, 2018
• Primary Completion (Estimated): November 8, 2028
• Study Completion (Estimated): November 8, 2029

Study Registration Dates

• First Submitted: April 29, 2021
• First Submitted That Met QC Criteria: June 23, 2021
• First Posted (Actual): July 1, 2021

Study Record Updates

• Last Update Posted (Actual): February 17, 2026
• Last Update Submitted That Met QC Criteria: February 11, 2026
• Last Verified: February 1, 2026

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Neoplasms
• Other Study ID Numbers: Pro00077309

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: De-identified data sets will be available upon requests following institutional approval.
• IPD Sharing Supporting Information Type: STUDY_PROTOCOL; ICF; CSR

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No